Strain Data Sheet

RBRC02768

Strain Information

Image
BRC No.RBRC02768
TypeTransgeneCartagena
SpeciesMus musculus
Strain nameC57BL/6J-Tg(InsBAC-TRECK/DTR)14Rin
Former Common name
H-2 Haplotype
ES Cell line
Background strainC57BL/6JJcl
Appearance
Strain developmentDeveloped by Kunie Matsuoka and Hiromichi Yonekawa, Tokyo Metropolitan Institute of Medical Science. The transgene was injected into the pronuclei of C57BL/6J fertilized eggs. RBRC02767 (line 5), RBRC02768 (line 14), RBRC02769 (line 17), RBRC02770 (line 33), RBRC02771 (scid background, the same line as the #70 in BBRC2013 article).
Strain descriptionINS2(BAC)-TRECK transgenic mice, expressing hDTR cDNA under the control of the mouse insulin II promoter. Hyperglycemia, severe ablation of pancreatic beta cells and depletion of serum insulin were observed within 3 days after the administration of DT.
Colony maintenance
References
Selective depletion of mouse kidney proximal straight tubule cells causes acute kidney injury.
Sekine M, Monkawa T, Morizane R, Matsuoka K, Taya C, Akita Y, Joh K, Itoh H, Hayashi M, Kikkawa Y, Kohno K, Suzuki A, Yonekawa H
Transgenic Res., 21(1):51-62 (2011). 21431867

Generation of mouse models for type 1 diabetes by selective depletion of pancreatic beta cells using toxin receptor-mediated cell knockout.
Matsuoka K, Saito M, Shibata K, Sekine M, Shitara H, Taya C, Zhang X, Takahashi T A, Kohno K, Kikkawa Y, Yonekawa H
Biochem. Biophys. Res. Commun., 436, 400-405 (2013). 23747725

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
HBEGF heparin-binding EGF-like growth factor (human)UNHBEGF mouse Ins2 promoter

Phenotype

Annotation by Mammalian phenotyhpe ontology
  • abnormal pancreatic alpha cell morphology(MP:0005216)
    • Detailed phenotype data

    Ordering Information

    Donor DNAMouse RP23-92L23 BAC clone, Human HB-EGF cDNA, (The cording region of mouse ins2 derived from a 280 kb BAC clone is substituted human diphtheria toxin receptor (HB-EGF) cDNA by homologous recombination)
    Research applicationDiabetes and Obesity Research
    covid19_progression
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Biochem. Biophys. Res. Commun., 436, 400-405 (2013).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT of BIOLOGICAL RESOURCE, who belongs to a profit organization must obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
    DepositorHiromichi Yonekawa (Tokyo Metropolitan Institute of Medical Science)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovery and QC required prior to distribution
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    BRC mice in Publications

    No Data